A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
ConditionAdvanced Breast Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAkeso
About this trial
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 combined with AK112 in advanced breast cancer.
Eligibility criteria
Qualifiers
Be able to understand and voluntarily sign the written informed consent form.
Aged of ≥ 18 years and ≤75 years.
ECOG PS 0 or 1.
The expected lifespan is ≥3 months.
Disqualifiers
Patients had breast cancer amenable to curative treatment at study enrollment.
Concurrent other histopathological types confirmed by tumor histology or cytology.
Having other active malignancies within 3 years.
Currently participating in another interventional clinical study.
Trial design
Treatments tested in this trial
- AK146D1 for injection
- AK112 Injection
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov